2017
DOI: 10.1093/neuonc/nox216
|View full text |Cite
|
Sign up to set email alerts
|

Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation—the NCT Neuro Master Match (N2M2) pilot study

Abstract: With this feasibility study, a comprehensive molecular profiling approach for patients with newly diagnosed glioblastoma harboring an unmethylated MGMT promoter is presented. Analyses in this pilot cohort serve as a basis for trials based on targetable alterations and on the question of allocation of patients to the best treatment arm.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
28
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
6
2

Relationship

3
5

Authors

Journals

citations
Cited by 35 publications
(28 citation statements)
references
References 40 publications
0
28
0
Order By: Relevance
“…A current concept prospectively using biomarkers to enrich for potentially benefitting patients is the Nationales Centrum für Tumorerkrankungen (NCT) Neuro Master Match (N 2 M 2 ), a trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation. 76 The Glioblastoma Adaptive, Global, Innovative Learning Environment (AGILE) consortium is planning to take a differential approach by reassessing potential biomarkers from an unselected cohort with given therapies first and integrating these information via adaptive processes to enrich while the trial accrues. 77 …”
Section: Discussionmentioning
confidence: 99%
“…A current concept prospectively using biomarkers to enrich for potentially benefitting patients is the Nationales Centrum für Tumorerkrankungen (NCT) Neuro Master Match (N 2 M 2 ), a trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation. 76 The Glioblastoma Adaptive, Global, Innovative Learning Environment (AGILE) consortium is planning to take a differential approach by reassessing potential biomarkers from an unselected cohort with given therapies first and integrating these information via adaptive processes to enrich while the trial accrues. 77 …”
Section: Discussionmentioning
confidence: 99%
“…O-6-methylguanine DNA methyltransferase promoter methylation is thought to result in lower expression of the protein that confers cellular resistance against alkylating chemotherapy agents such as temozolomide, one of the mainstays of glioma chemotherapy. 31,32 Evidence also suggests that MGMT promoter methylation may be a reflection of global DNA hypermethylation that ultimately predicts better prognosis and response to therapy. 33,34 How Do IDH Mutations Contribute to Tumorigenesis?…”
Section: What Role Does Molecular Diagnostics Play In the Classificatmentioning
confidence: 99%
“…This also demonstrates the successful interaction with another German Center of Health Research. Another example is the molecularly stratified umbrella trial NCT Neuro Master Match (N 2 M 2 ), which has started recruiting adult patients with glioma at all DKTK sites (Pfaff et al, 2018;Wick et al, 2019). The clinical impact of this research approach is demonstrated by major contributions, which DKTK research could make to novel tumor classification schemes, as for example, the WHO Classification of Brain Tumors (Louis et al, 2016) or EANO guidelines for the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas (Weller et al, 2017) and ependymal tumors (Ruda et al, 2018).…”
Section: Examples Of Major Scientific Highlightsmentioning
confidence: 99%